Friday, July 10, 2026

pharma · Multiple Myeloma · Neoplasms

Teva/Actavis Generics

Teva/Actavis Generics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Salt Lake City, USA HQ
1992 Founded
100 Employees
EMA registrant Type
Company details
Status
Public
HQ
Salt Lake City, USA
Founded
1992
Employees
100
Programs
4
Drugs
1
Patents
0
Intelligence · Clinical Programs

Teva/Actavis Generics projects

4 ClinicalTrials.gov programs sponsored by Teva/Actavis Generics.

Teva/Actavis Generics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Reslizumab

    Teva Generics B.V

    Eosinophilic Asthma

    phase 3 small molecule terminated

    1 trial
  2. TEV-56248

    Teva Generics B.V

    Asthma

    phase 3 small molecule active

    1 trial
  3. CEP-18770

    Teva Generics B.V

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  4. Modakafusp Alfa

    Teva Generics B.V

    Neoplasms

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Teva/Actavis Generics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.